Post

Moderna reports net loss of $4.7bn for full year 2023

Moderna has reported a net loss of $4.7bn for the full year 2023 as against a net income of $8.4bn …

NICE recommends Pfizer’s Ritlecitinib for alopecia areata treatment

The UK National Institute for Health and Care Excellence (NICE) has recommended Pfizer's Ritlecitinib, marketed as Litfulo, as a new …

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, …

AbbVie and Tentarix enter biologic development deal

AbbVie has signed a strategic partnership agreement with Tentarix Biotherapeutics to discover and develop new conditionally active, multi-specific biologic candidates …

Digital transformation of the supply chain will make data more valuable – are you prepared?

It has been a long decade for the pharmaceutical industry. Some changes, like the pace of innovation and influx of …